BRAF V600E-positive melanoma
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
melanoma subtype
|
| gptkbp:aminoAcidChange |
valine to glutamic acid at position 600
|
| gptkbp:associatedWith |
aggressive tumor behavior
increased MAPK pathway activation resistance to some therapies |
| gptkbp:containsGene |
gptkb:BRAF
|
| gptkbp:diagnosedBy |
molecular testing
|
| gptkbp:foundIn |
metastatic melanoma
cutaneous melanoma |
| gptkbp:hasTargetedTherapy |
gptkb:BRAF_inhibitors
gptkb:MEK_inhibitors |
| https://www.w3.org/2000/01/rdf-schema#label |
BRAF V600E-positive melanoma
|
| gptkbp:ICD-10_code |
gptkb:C43
|
| gptkbp:mutationAssociatedWith |
gptkb:BRAF_V600E
|
| gptkbp:prevalence |
about 40-60% of cutaneous melanomas
|
| gptkbp:prognosis |
variable
|
| gptkbp:subjectOf |
clinical trials
|
| gptkbp:treatment |
gptkb:encorafenib
gptkb:dabrafenib gptkb:vemurafenib combination therapy with MEK inhibitors |
| gptkbp:bfsParent |
gptkb:PLX4032
|
| gptkbp:bfsLayer |
7
|